0.446
0.38%
0.0017
After Hours:
.46
0.014
+3.14%
Athira Pharma Inc stock is traded at $0.446, with a volume of 414.27K.
It is up +0.38% in the last 24 hours and down -85.57% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
See More
Previous Close:
$0.4443
Open:
$0.4565
24h Volume:
414.27K
Relative Volume:
0.60
Market Cap:
$17.08M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1576
EPS:
-2.83
Net Cash Flow:
$-101.06M
1W Performance:
+6.19%
1M Performance:
-85.57%
6M Performance:
-83.72%
1Y Performance:
-77.92%
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Jul-07-22 | Initiated | Mizuho | Buy |
Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
Jun-23-22 | Downgrade | Stifel | Buy → Hold |
May-10-22 | Initiated | BTIG Research | Buy |
Apr-21-22 | Initiated | Berenberg | Buy |
Dec-15-21 | Initiated | Goldman | Neutral |
Oct-13-20 | Initiated | Goldman | Buy |
Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
Oct-13-20 | Initiated | Jefferies | Buy |
Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com India
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com India
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - StockTitan
Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex
Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News
Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily
Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex
AdPha urges HTA reform - Pharmacy Daily
Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today
Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia
Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com
Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily
ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily
Closing Bell Recap: Athira Pharma Inc (ATHA) Ends at 0.54, Reflecting a -3.65 Downturn - The Dwinnex
StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial - Genetic Engineering & Biotechnology News
Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com Australia
Athira Pharma (ATHA) Stock Price, News & Analysis - MarketBeat
Athira Pharma COO Rachel Lenington sells shares worth $1,429 - Investing.com India
Athira plunges as Alzheimer’s trial setback leads to downgrades - MSN
Athira Pharma CEO sells over $2.8k in company stock - Investing.com
Athira Pharma COO Rachel Lenington sells shares worth $1,429 By Investing.com - Investing.com Canada
Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com UK
Athira Pharma executive sells shares worth $1,429 By Investing.com - Investing.com UK
Athira Pharma tanks as fosgonimeton misses in Alzheimer’s trial | Pharmaceutical | The Pharmaletter - The Pharma Letter
Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral - Defense World
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):